Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Spyre Therapeutics, Inc. (SYRE) had Return on Equity of -3.79% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-36.20M |
|
-- |
|
-- |
|
$41.64M |
|
$-41.64M |
|
$5.44M |
|
$-36.20M |
|
$-36.20M |
|
$-36.20M |
|
$-36.20M |
|
$-36.20M |
|
$-36.20M |
|
$-41.64M |
|
$-41.64M |
|
84.73M |
|
84.73M |
|
$-0.36 |
|
$-0.36 |
|
| Balance Sheet Financials | |
$1.17B |
|
-- |
|
-- |
|
$1.17B |
|
$63.30M |
|
-- |
|
$8.56M |
|
$71.86M |
|
$954.72M |
|
$1.10B |
|
$1.10B |
|
88.06M |
|
| Cash Flow Statement Financials | |
$-127.25M |
|
$-241.32M |
|
$444.86M |
|
$85.72M |
|
$162.01M |
|
$76.29M |
|
$26.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
18.53 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-127.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-3.79% |
-3.29% |
|
-3.09% |
|
-3.29% |
|
$12.50 |
|
$-1.50 |
|
$-1.50 |
|